Chemotherapy plus targeted therapy for older adults with mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of chemotherapy and targeted therapy as the first treatment for older adults with mantle cell lymphoma. The treatment is guided by regular scans and blood tests (PET-CT and MRD) to see how well it's working and to adjust it if needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 or older, or you are 60-64 and not able or willing to have a stem cell transplant.
- You have been diagnosed with mantle cell lymphoma (stage II, III, or IV) and have not had any treatment yet.
- You are generally able to care for yourself (ECOG score 0-2).
- Your blood counts and liver/kidney function are within acceptable levels.
- You do not have serious heart problems, active bleeding, recent blood clots, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether an “extra chemo” schedule (adding cytarabine) can work better than a standard rituximab-bendamustine plan in older people with mantle cell lymphoma. It compares two treatment sequences to see which one helps patients live longer and respond better with acceptable safety.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This study tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) to see if it is safe and effective for people with a fast-growing or hard-to-treat type of mantle cell lymphoma. If you have high-risk features, this therapy might be an option.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.